Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1

Conditions

Head and Neck Neoplasms 2103Squamous Cell Carcinoma of Head and Neck 1654Nasopharyngeal Carcinoma 517Thyroid Neoplasms 478Carcinoma, Non-Small-Cell Lung 438Breast Neoplasms 315Mouth Neoplasms 312Neoplasms 309Melanoma 299Oropharyngeal Neoplasms 285Colorectal Neoplasms 274Lung Neoplasms 248Carcinoma, Squamous Cell 240Neoplasm Metastasis 235Ovarian Neoplasms 228Uterine Cervical Neoplasms 204Stomach Neoplasms 195Salivary Gland Neoplasms 192Laryngeal Neoplasms 192Nasopharyngeal Neoplasms 189Carcinoma, Renal Cell 183Esophageal Neoplasms 179Pancreatic Neoplasms 176Prostatic Neoplasms 158Sarcoma 142Triple Negative Breast Neoplasms 136Urinary Bladder Neoplasms 135Recurrence 128Endometrial Neoplasms 124Hypopharyngeal Neoplasms 121

Interventions

spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Disorders of Sex Development × Head & Neck × Clear all
NCT02605967 2022-02-10

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Novartis

Phase 2 Completed
122 enrolled 28 charts
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Recurrence, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡